A peptide that tightens up the seals between your gut lining cells, directly addressing "leaky gut" (where stuff slips through gaps it shouldn't). Originally developed for celiac disease, but useful for anyone dealing with gut barrier problems or autoimmune conditions.
What to Expect
Week 1–2
Tightening of intestinal tight junctions beginning. Reduced gut permeability. Subtle improvement in food-sensitivity reactions.
Week 3–6
Significant reduction in leaky gut symptoms. Improved tolerance of gluten (in celiac patients). Reduced bloating and GI discomfort.
Week 8+
Sustained intestinal barrier restoration. Reduced systemic inflammation from gut permeability. Improved nutrient absorption.
Common Side Effects
Dosing
0.5-1 mg by mouth 3 times daily before meals. Cycle for 8-12 weeks.
Practical Guide
Storage
Store capsules at room temperature. Oral medication — no reconstitution needed.
Timing
Three times daily, 15 minutes before each meal. Consistent pre-meal timing is important for efficacy.
Food
Take 15 minutes before meals for optimal tight junction activity during food exposure.
Benefit Profile
Medical Considerations
Contraindications
- ✕Pregnancy/nursing
- ✕Known hypersensitivity to peptide components
Drug Interactions
Recommended Monitoring
- →Tissue transglutaminase (tTG) antibodies
- →GI symptom tracking
- →Nutritional markers (iron, B12, folate)
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Pricing
| Vendor | Variant | Price | |
|---|---|---|---|
| Limitless Biotech | 30ct | $49.99BEST | Code: PSTACK10Buy |
Published Research
Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.
New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review.
Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
Celiac disease: Hope for new treatments beyond a gluten-free diet.
Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions.